GLP-1 and Eating Disorders, is it a good idea?

By Margaret DeCosta PMHNP

If you or someone you love has an eating disorder, you may be wondering whether a GLP-1 medication such as semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide, or dulaglutide (Trulicity) could help. This blog explains why these medications are generally not safe or appropriate for people with eating disorders, and why a restrictive eating disorder is considered a reason not to use them.

The most important idea to understand first: an eating disorder is a mental health illness, not a weight problem. Because of that, a medication that changes the number on the scale does nothing to treat the illness itself and it can make it worse. An eating disorder is an illness of the brain, not the body. It is easy to think of an eating disorders as being "about food" or "about weight." They are not. Eating disorders are serious psychiatric (mental health) illnesses. What you see on the outside- restricting food, bingeing, purging, over-exercising, or weight change are the visible symptoms. The actual illness lives in how the brain thinks and feels about food, body, and self-worth. At the center of most eating disorders are things like:

● An intense fear of weight gain, or a distorted view of one's own body

● Self-worth that feels tied to weight, shape, or the ability to control eating

● A loss of control around food, or a powerful drive to restrict it

● Deep distress, anxiety, perfectionism, and often depression underneath the behaviors

These illnesses change the way brain circuits handle reward, habit, anxiety, and the sense of self. That is why they are so hard to simply "decide" your way out of and why they are treated as medical and psychiatric conditions, not lifestyle choices or willpower failures.

Importantly, obesity is not an eating disorder, and an eating disorder is not defined by

body size. People with eating disorders can be underweight, average weight, or in larger

bodies. Someone can be losing weight and getting sicker at the same time. This is exactly why treating the weight does not treat the disease. Why "fixing the number on the scale" does not fix the illness. Because the illness is in the mind, changing body weight leaves the core problem untouched. If a person restricts food and loses weight, the fear, the distorted body image, the anxiety, and the self-criticism are all still there. Often they get worse, because the eating disorder is being "fed" by the restriction and weight loss. Real recovery works on the illness itself the thoughts, fears, emotions, and behaviors usually through:

● Psychotherapy (talk therapy), which is the foundation of treatment

● Nutritional support and restoring regular, adequate eating

● Treating co-occurring depression, anxiety, or other conditions, sometimes with

medication

● Medical monitoring for the physical effects of the illness

A medication whose main job is to shrink appetite and body weight is aimed at the wrong target entirely. What GLP-1 medications actually do is lower appetite, increase the feeling of fullness, slow how fast the stomach empties, and reduce food-related cravings and "food noise." For a person with type 2 diabetes or obesity without an eating disorder, that can be helpful. But now put those same effects into the mind of someone with an eating disorder. A medication that powerfully suppresses appetite and drives weight down can act like a tool that helps the eating disorder do exactly what it wants to do restrict food, avoid eating, and lose weight. Instead of fighting the illness, the medication can strengthen it.

Why GLP-1 Medications are Considered Off-limits in Eating Disorders

Several major medical organizations and reviews have raised clear warnings:

● A joint advisory from leading obesity and nutrition organizations states that everyone

considered for a GLP-1 should be screened for eating disorders first, and that a restrictive eating disorder is a general reason not to use these medications. Anyone with a history of an eating disorder should be evaluated by both an obesity medicine specialist and an eating disorder specialist before these drugs are even considered.

● There are no eating disorders for which GLP-1 medications are an approved treatment. They are approved for type 2 diabetes, obesity, cardiovascular risk, kidney disease, and sleep apnea not for anorexia, bulimia, or binge eating disorder.

● Doctors have reported cases where GLP-1 medications led to extreme appetite loss,

dangerous food restriction, and psychiatric problems, sometimes requiring the medication to be stopped.

● Studies have found that some people with eating disorders are already using or

misusing these medications in harmful ways to fuel restriction and rapid weight loss

which keeps the eating disorder going.

There is some early, mixed research suggesting these drugs might reduce binge-eating

episodes for certain people. But the evidence is limited and inconsistent, the same appetite-suppressing effects can trigger harmful restriction, and none of this makes GLP-1s a safe or approved treatment for an eating disorder. These are questions for specialists, not reasons to start the medication on your own.

The Real Dangers

Eating disorders are among the most serious of all mental illnesses. They can affect nearly every organ in the body the heart (dangerously slow or irregular heartbeat), electrolytes (which can be life-threatening), bones, hormones, and the digestive system. Anorexia nervosa in particular carries one of the highest death rates of any psychiatric illness, and a large share of those deaths are from suicide. Depression and suicidal thinking are common across eating disorders.

Adding a medication that further suppresses appetite and encourages weight loss into this picture can accelerate the physical harm and deepen the psychological illness.

What Actually Helps

If you have an eating disorder at any body size the path forward is treatment aimed at the illness itself, guided by professionals who understand eating disorders. That means therapy, nutritional support, care for your mental health, and medical follow-up. It does not mean a weight-loss injection.

If you are currently taking a GLP-1 medication and have an eating disorder or are worried about your relationship with food, do not simply start or stop the medication on your own. Talk openly with your doctor and an eating disorder specialist so decisions can be made safely.

When to Reach Out Right Away

Please seek help promptly if you notice:

● Fainting, chest pain, a racing or very slow heartbeat, or severe weakness

● Vomiting, an inability to keep food or fluids down, or rapid weight loss

● Feelings of hopelessness, or thoughts of harming yourself

You deserve care that treats the whole illness your mind and your body not just a number on a scale.

Resources

American Psychiatric Association. (2026) Diagnostic and statistical manual of mental disorder, fifth edition, text revision (DSM-5-TR). https://www.appi.org/products/dsm

Bartel, S., McElroy, S. L., Levangie, D. and Keshen, A. (2023). Use of glucagon-like peptide-1 recptor agonists in eating disorder population. Eating Disorders, 57 (2), 286-293. doi: 10.1002/eat.24109

Budia, J. M., Alcover, C. M., ... Felix-Alcantara, M. P. (2023) Attachment, motivational systems and anorexia nervosa: A systematic review and proposed framework for eating disorders. Clinical Psychology and Psychotherapy, 30(5), 913-930. doi: 10.1002/cpp.2845

Attia, E. and Walsh, J. (2025) Eating disorders, a review. JAMA, 333 (4). doi: 10.1001/jama.2025.0132

Han, S., Yang, Y., Liu, Y., ... Zhang, H. (2026). Association of glucagon-like peptide-1 receptor agonist use with risk of psychiatric disorders: a systematic review and meta-analysis of randomised controlled trials. Diabetes Obesity and Metabolism, 28 (6), 5011-5019. doi: 10.1111/dom.70692

Jebeile, H., Danielsen, Y. S., ... Lister, N. B. (2026) GLP-1 receptor agonist medications for obesity and type 2 diabetes treatment: a rapid review of changes in eating behaviors and eating disorder risk. Obesity Reviews, 27 (4). doi: 10.1111/obr.70049

Leziak, A. Kochman, K. and Kocetak, P. (2026) The dual role of GLP-1 receptor agonist in weight management and eating disorders: Potential benefits and risks. Journal of Psychiatric Research, 197, 243-249.

Mozaffaran, D., Agarwal, M., Alexander, L., ... Callahan, E. (2025) Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory fron the American Society for Nutrition, the Obesity Medicine Society. The American Journal of Clinical Nutrition, 122, 344-367.

Peiper, N. C., Zibbell, J. E. and LaJoie, A. S. (2026) Use and misuse of GLP-1 receptor agonist among people with eating disorders. JAMA Psychiatry, 83 (8), 880-882. doi: 10.1001/jamapsychiatry. 2026.1716

Skudar, S. (2026) Eating disorders in the GLP-1 era: A spotlight on emergingclinical risks, research gaps, and practice priorities. International Journal of Eating Disorders. doi: 10.1002/eat.70145

Smitka, K., Papezova, H., ... Nedvidkova, J. (2013). The role of ‘‘mixed’’ orexigenic and anorexigenic signals and autoantibodies reacting with appetite-regulating neuropeptides and peptides of the adipose tissue-gut-brain axis: Relevance to food intake and nutritional status in patients with anorexia nervosa and bulimia nervosa. International Journal of Endocrinology, 2013(1), 1-21.

Treasure, J. Duarte, T. A. and Schmidt, U. (2020) Eating disorders. The Lancet, 395, 899-911.

US Preventive Service Task Force. (2022) Screening for Eating Disorder in Adolescent and Adults. JAMA, 347(11), 1061-1067. doi: 10.1001/jama.2022.1806